Aberdeen Group’s GeneDx Holdings WGS Stock Holding History

Aberdeen Group’s Portfolio WGS Stock Details WGS Fund Activity

Bought

Maintained

Sold

Quarter	Market Value	Status	Shares	Change in Stake	Trade Value	Portfolio Weight	Portfolio Position
2026 Q2	$31.4M	Buy	457,201 +227,105	+99%	+$12.9M	0.04%	325
2026 Q1	$14.8M	Buy	+230,096	New	+$21M	0.02%	501
2025 Q3	–	Sell	-136,732	Closed	-$12.6M	–	984
2025 Q2	$12.6M	Buy	+136,732	New	+$10.7M	0.02%	545

Other funds holding WGS

Corvex Management New York $3.27B AUM 38.53% 1-Year Est. Return

Casdin Capital New York $2B AUM 147.21% 1-Year Est. Return

BlackRock New York $6.73T AUM 46.02% 1-Year Est. Return

Goldman Sachs New York $1.15T AUM 47.82% 1-Year Est. Return

AIM

ARK Investment Management St. Petersburg, Florida $15.4B AUM 50.29% 1-Year Est. Return

William Blair Investment Management Chicago, Illinois $33.3B AUM 44.76% 1-Year Est. Return

Morgan Stanley New York $1.89T AUM 35.08% 1-Year Est. Return

Vanguard Capital Management Malvern, Pennsylvania $4.68T AUM

Citadel Advisors Miami, Florida $875B AUM 40.91% 1-Year Est. Return

FLAM

First Light Asset Management Edina, Minnesota $1.65B AUM 203.21% 1-Year Est. Return

Aberdeen Group's WGS Position: Q2 2026 in Review

Aberdeen Group increased its GeneDx Holdings (WGS) stake by 99% in Q2 2026, buying an estimated $12.9M and bringing the position to 457,201 shares worth $31.4M. The position accounts for 0.04% of the portfolio, ranked #325.

Aberdeen Group first reported a position in WGS in Q2 2025 and has held it in 3 quarters since. 223 funds tracked by Wall St. Rank hold WGS as of Q2 2026.

Aberdeen Group held 457,201 shares of GeneDx Holdings worth $31.4M as of Q2 2026.
Aberdeen Group bought 227,105 GeneDx Holdings shares in Q2 2026, an estimated $12.9M.
GeneDx Holdings made up 0.04% of Aberdeen Group's portfolio in Q2 2026, its #325 holding.
Aberdeen Group first reported a position in GeneDx Holdings in Q2 2025 and has held it in 3 quarters since.
223 funds tracked by Wall St. Rank held GeneDx Holdings as of Q2 2026.

Based on Aberdeen Group's 13F filing for Q2 2026, filed 31 Jul 2026.